Mr. Driscoll was counsel for 63 plaintiffs in Austin, et al. v. Sanofi-Aventis U.S. LLC (Case No. 07-L-525; St. Clair Co., Illinois), involving the drug Ketek.
Mr. Driscoll successfully resolved the claims of 9 plaintiffs in Madison County, Illinois in White, et al. v. Pfizer, Inc., et al. (Case No. 2007-L-325) and in Wiese, et al. v. Pfizer, Inc., et al. (Case No. 007-L-324) in claims involving Celebrex (confidential settlement).
Mr. Driscoll resolved 28 pharmaceutical product liability claims to the satisfaction of 28 women alleged to have suffered injury from the birth control patch Ortho Evra (confidential settlement).
Mr. Driscoll was involved in the successful resolution of several cases in the Phenylpropanolamine (PPA) litigation. He litigated Keller v. Wyeth, Inc., et al. (Case No. 09-MI-304007); and Angelopoulos v. GlaxoSmithKline PLC, et al. (Case No. 03-L-014511) (confidential settlement) in Cook County, Illinois.
Mr. Driscoll successfully resolved the claims of approximately 232 plaintiffs in the U.S. District Court for the District of Minnesota alleging injury from defective defibrillators manufactured by Guidant Corporation (confidential settlement), and other plaintiffs alleging injury from defective defibrillators manufactured by Medtronic (settlement pending).
Mr. Driscoll represented 18 plaintiffs alleged to have been stricken with Nephrogenic Fibrosing Dermopathy, a rare incurable skin disorder caused by the injection of an MRI contrast agent, Omniscan, manufactured by General Electric. McCallum, et al. v. General Electric Company, et al. (08-L-394; St. Clair County, Illinois).
Mr. Driscoll represented more than 1,705 plaintiffs in pharmaceutical injury claims against SmithKline Beecham and GlaxoSmithKline.
Mr. Driscoll represents plaintiffs in 49 claims pending in the Eastern District of Pennsylvania, Avandia MDL-1871, involving the pharmaceutical product Avandia.